We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Paragon 28, Inc. (FNA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Paragon 28, Inc. is one of 1160 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Paragon 28, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for FNA's full-year earnings has moved 6.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that FNA has returned about 2.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 9.9% on average. This means that Paragon 28, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Gamida Cell . The stock has returned 48% year-to-date.
In Gamida Cell's case, the consensus EPS estimate for the current year increased 26.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Paragon 28, Inc. belongs to the Medical - Instruments industry, a group that includes 102 individual stocks and currently sits at #179 in the Zacks Industry Rank. On average, stocks in this group have lost 19% this year, meaning that FNA is performing better in terms of year-to-date returns.
On the other hand, Gamida Cell belongs to the Medical - Biomedical and Genetics industry. This 540-stock industry is currently ranked #157. The industry has moved -17.7% year to date.
Investors interested in the Medical sector may want to keep a close eye on Paragon 28, Inc. and Gamida Cell as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Paragon 28, Inc. (FNA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Paragon 28, Inc. is one of 1160 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Paragon 28, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for FNA's full-year earnings has moved 6.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that FNA has returned about 2.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 9.9% on average. This means that Paragon 28, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Gamida Cell . The stock has returned 48% year-to-date.
In Gamida Cell's case, the consensus EPS estimate for the current year increased 26.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Paragon 28, Inc. belongs to the Medical - Instruments industry, a group that includes 102 individual stocks and currently sits at #179 in the Zacks Industry Rank. On average, stocks in this group have lost 19% this year, meaning that FNA is performing better in terms of year-to-date returns.
On the other hand, Gamida Cell belongs to the Medical - Biomedical and Genetics industry. This 540-stock industry is currently ranked #157. The industry has moved -17.7% year to date.
Investors interested in the Medical sector may want to keep a close eye on Paragon 28, Inc. and Gamida Cell as they attempt to continue their solid performance.